Hemostemix Up-lists to TradeGateExchange in Germany

Rhea-AI Summary

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced its listing on the TradeGateExchange.De under symbol 2VF0, effective January 27, 2025. The company's management and directors have invested over $9.1 Million since 2020.

The company's product, ACP-01, has demonstrated safety across 498 treatments, with results documented in seven studies involving 318 subjects and nine peer-reviewed publications. The treatment shows efficacy in limb salvation, heart function regeneration, and mental acuity improvement.

The TradeGateExchange listing offers several benefits including extended trading hours, real-time market data, competitive fee structures, efficient order execution, and enhanced accessibility for European investors.

Positive

• Management and directors have invested over $9.1 Million since 2020
• ACP-01 treatment has proven safety record in 498 treatments
• Clinical data supported by seven studies with 318 subjects
• Research validated through nine peer-reviewed publications
• Expanded market access through TradeGateExchange listing

Negative

• None.

Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares commenced trading on the TradeGateExchange.De under symbol 2VF0 today, January 27, 2025.

"Listing on the TradeGateExchange.De enables Hemostemix to investors in the Europe, the EU, UK, to buy into their Fountain of Youth and longevity, directly. As management and directors, we have invested greater than $9.1 Million in Hemostemix's since 2020. We did so because ACP-01 works: it saves limbs from amputation; it regenerates heart function; it regenerates mental acuity. It is clinically relevant; it is statistically significant; it is completely safe in 498 treatments, which is all detailed in seven studies of 318 subjects, in nine peer review publications. My question to anyone who wants to enjoy the quality of life they have well into their old age is: why wait for a disease process? Why not invest in Your Fountain of Youth today? That is why we trademarked Your Fountain of Youth. It is real. That is the message we are getting across to investors who trade on the TradeGateExchange, " Thomas Smeenk, CEO, said.

Trading on the TradeGateExchange generates the following opportunities for Hemostemix:

1. Competitive Trading Hours: With extended trading hours, TradeGate allows purchases of Hemostemix shares over a broader time frame, enabling shareholders to react promptly to the Company's developments.

2. Real-Time Market Data: The platform offers up-to-date market information, ensuring traders have access to the latest share price, to make informed decisions.

3. Cost-Effective Trading: Competitive fee structures make trading on TradeGate an economical choice for managing investment costs.

4. Efficient Order Execution: TradeGate ensures swift and reliable order processing, minimizing delays and slippage in trade executions.

5. Dedicated Customer Support: A responsive customer service team is available to assist traders with any inquiries or issues they may encounter.

6. Commitment to Sustainability: TradeGate is dedicated to sustainable practices, investing in people, technology, and infrastructure to empower communities and conserve the planet.

7. User-Friendly Interface: TradeGate's platform is designed for ease of use, catering to both novice and experienced traders with intuitive navigation and tools.

8. Robust Security Measures: TradeGate prioritizes the security of its users' data and transactions, implementing advanced security protocols to protect against unauthorized access.

9. Educational Resources: The platform provides educational materials and training programs to help traders enhance their knowledge and skills.

About Hemostemix

Founded in 2003, Hemostemix is a clinical-stage biotechnology company recognized for its patented blood-based stem cell therapeutics platform. Hemostemix is focused on scaling angiogenic, neuronal, and cardiomyocyte cell precursors, to treat no-option patients worldwide.

Learn more: www.hemostemix.com

Contact: Thomas Smeenk, President & CEO - tsmeenk@hemostemix.com | (905) 580-4170

Stock Information: (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0)

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Program. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238602

FAQ

When did HMTXF start trading on TradeGateExchange?

Hemostemix (HMTXF) commenced trading on TradeGateExchange.De under symbol 2VF0 on January 27, 2025.

How much have Hemostemix insiders invested since 2020?

Management and directors have invested more than $9.1 Million in Hemostemix since 2020.

What are the clinical results of HMTXF's ACP-01 treatment?

ACP-01 has demonstrated safety in 498 treatments, showing efficacy in saving limbs from amputation, regenerating heart function, and improving mental acuity, supported by seven studies with 318 subjects.

How many peer-reviewed publications support HMTXF's research?

Hemostemix's research is supported by nine peer-reviewed publications.

What benefits does the TradeGateExchange listing offer HMTXF investors?

The listing offers extended trading hours, real-time market data, competitive fee structures, efficient order execution, and improved accessibility for European investors.